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Abstract
Background: Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is associated with
poorer response to chemotherapy and chemoradiotherapy.
Case presentation: A 27-year-old Swedish woman presented with stomach pain and weight loss, and was diagnosed
with locally advanced MAC in the transverse colon as well as 3 liver metastases. Neoadjuvant treatment with
fluorouracil, folinic acid and oxaliplatin (FLOX) failed due to several infections, pulmonary embolism and deteriorated
performance status. The patient was therefore considered palliative. Palliative treatment with metronomic capecitabine
500 mg × 2 daily and bevacizumab every other week were initiated. After 4 months of treatment the tumors had
regressed and the patient was able to undergo radical surgery, thereby changing the treatment intention from
palliative to curative. No adjuvant chemotherapy was given. There were no signs of recurrence 9 months later.
Conclusions: The role of the combination of metronomic capecitabine and bevacizumab in patients with MAC merits
further investigation.
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Background
Mucinous adenocarcinoma (MAC) represents about
6–19 % of colorectal carcinomas (CRC) [1]. The WHO
defines MAC as an adenocarcinoma in which at least
50% of the cancer tissue is composed of mucin [2].
Numerous studies have shown conflicting results re-
garding the prognosis of MAC compared to the more
common non-mucinous adenocarcinoma (NMAC) [2, 3].
It has however been shown that MAC is less likely to be
resected with negative surgical margins [4], more often
metastasizes to lymph nodes [5, 6] and generally presents
at a later stage compared to NMAC [2]. MAC is also more
prone to local recurrence [4, 7] as well as peritoneal car-
cinomatosis [6, 8]. Although the characteristics of MAC
have not been fully clarified, due to the low incidence of
this type of tumor, studies have shown that MAC shows
less p53 and p21 expression and less APC mutations com-
pared to NMAC [2]. There also appears to be an increased
frequency in BRAF mutation [1] and increased microsatel-
lite instability (MSI) [9]. In our clinic it is not praxis to
analyze these markers because the results would not affect
our choice of treatment.
Compared to NMAC, MAC is associated with a
poorer response to chemotherapy and chemoradiother-
apy [10, 11], resulting in some restrictiveness to treat-
ment. Here, we present a case of successful preoperative
treatment and surgery of a patient with stage IV MAC.
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Case presentation
A 27-year-old Swedish woman with no family history of
cancer presented with stomach pain, rectal bleeding and
weight loss. A computed tomography (CT) revealed an
80 × 55 mm tumor in the transversal colon. Colonos-
copy showed a stricturating, voluminous tumor with
irregular polyps. Most of the tumor surface was covered
with white necrotic tissue. Multiple biopsies from the
site showed suspected adenocarcinoma, but the result
was not conclusive. A biopsy was then taken from the
abdominal wall, and MAC with K-ras mutation in codon
12, gene pGly 12ASP (c.35G > A) was found.
Two months after the prior CT, a new CT showed that
the tumor had grown rapidly, measuring 150 × 90 mm
(Fig. 1a). It was locally advanced, seemed to infiltrate the
duodenum and the mesentery, and involved the abdom-
inal wall. Moreover, 3 small liver metastases were discov-
ered, sized 12 mm, 7 mm and 4 mm, respectively.
Carcinoembryotic antigen (CEA) was <5 μg/L and cancer
antigen 19–9 (CA 19–9) was 27 kE/L, both within the
normal range.
The primary tumor was originally considered non-
resectable at multidisciplinary conference (MDC) and
chemotherapy with neoadjuvant intention was initiated.
The patient received 3 cycles of fluorouracil and oxali-
platin (FLOX), but unfortunately suffered from several
infections and the dose was gradually reduced (Table 1).
Even so, she rapidly deteriorated. She lost weight, slept
most of the day and was dependent on parenteral nutri-
tion (Table 1). She had anemia, thrombocytosis and
hypoalbuminemia (Fig. 2), and also suffered from a
pulmonary embolism. A CT scan showed similar tumor
size compared to the previous CT (Fig. 1b).
The therapy was now focused on palliation and she
was referred to palliative care. The treatment was
switched to low dose metronomic (LDM) capecitabine
500 mg × 2 (500 mg twice daily without interruption)
and bevacizumab 350 mg every other week. Within a
short time she began to feel better, being able to stay up
most of the day. After 2 months she described herself as
feeling fresh and alert, and had gotten her appetite back.
Her blood tests were restored to normal. After 3 months
she was no longer in need of parenteral nutrition. She
did not report any side effects of the given treatment.
After 4 months a CT showed some regression in tumor
size but clearly less solid component and low attenuating
Fig. 1 A computed tomography (CT) with contrast before treatment (a), 2 months after FLOX treatment (b), 4 months after treatment with metronomic
capecitabine/bevacizumab (c) and 9 months after surgery (d)
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areas, indicating necrosis (Fig. 1c). At a new MDC the
tumor was deemed resectable. Four and a half months
after she began treatment with capecitabine/bevacizu-
mab, she had surgery with right hemicolectomy, mesen-
tery resection and omentectomy. Parts of the right
rectus abdominis muscle were removed along with the
tumor overgrowth. In the same operation, 3 of the liver
metastases in segments 1, 3 and 4b were also removed.
Yet another liver metastasis in segment 8 was identified
with intraoperative contrast-enhanced ultrasound. It
measured 5–6 mm and was treated with intraoperative
radiofrequency treatment. Histopathological examination
confirmed the diagnosis of a moderately differentiated
MAC in the colon, measuring 90 × 60 mm. (Fig. 3) In
addition, there was an 80x80 mm portion of the tumor
that engaged the abdominal wall. There were large
areas of necrosis in the tumor. Perineural growth was
seen but no lymphovascular invasion. None of the 34
surgically removed lymph nodes contained metastasis.
In the liver, 3 metastases of MAC were found, measur-
ing 15 × 18 mm, 6 × 15 × 8 mm and 18 × 15 × 11 mm,
respectively. There was also an incidental finding of a
neuroendocrine tumor grade 1, pT1a, in the appendix.
The patient suffered from a postoperative infection,
but recovered well. No adjuvant chemotherapy was
given. She is under follow up and there are no signs of
recurrence 9 months (Fig. 1d) after surgery.
Discussion
There have been several studies with conflicting results
regarding the prognosis of patients with MAC compared
to NMAC [2, 3]. A meta-analysis from 2011, with 44
Table 1 Patient’s BMI, chemotherapy doses given and performance status
Year Month BMI Treatment Dose Performance status
2011 31.2
2013 Feb 29.4 FLOX C1 Oxaliplatin: 150 mg Fluorouracil: 950 mg Calciumfolinat: 110 mg 0
March 28.7 FLOX C2 Oxaliplatin: 140 mg Fluorouracil: 900 mg Calciumfolinat: 100 mg 1
April 27.8 FLOX C3 Oxaliplatin: 120 mg Fluorouracil: 720 mg Calciumfolinat: 100 mg 1
June 29.2 Capecitabine 500mgx1 1-2
July Capecitabine/ Bevacizumab C1 500 mg × 2/ 350 mg 1-2
Aug Capecitabine/ Bevacizumab C2 500 mg × 2/ 350 mg 0-1
Capecitabine/ Bevacizumab C3 500 mg × 2/ 350 mg
Sept Capecitabine/ Bevacizumab C4 500 mg × 2/ 350 mg
Capecitabine/ Bevacizumab C5 500 mg × 2/ 350 mg
Oct 29.8 Capecitabine/ Bevacizumab C6 500 mg × 2/ 350 mg 0-1
Capecitabine/ Bevacizumab C7 500 mg × 2/ 350 mg













Fig. 2 Platelet concentration (TPC), hemoglobin (Hb) and albumin levels over time during treatment
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studies and 222 256 patients with CRC included, stated
that mucinous differentiation resulted in an increased
hazard of death [2]. It has been suggested that a worse
prognosis could be due to the fact that MAC more often
present at a more advanced stage [12], but the meta-
analysis from 2011 showed that a worse prognosis per-
sisted after correction for stage [2].
On the other hand, in 2012 a study of 244 794 patients
with CRC showed that there was no difference between
the groups when MAC was located in the colon. The
exception was signet-ring cell adenocarcinoma, which
had a significantly worse prognosis, regardless of stage
and location.
A disadvantage when comparing studies including
patients with MAC is that even though WHO has defined
MAC, several studies have used their own definition, often
with a higher percentage of mucinous component, and no
distinction between MAC and signet-ring cell carcinoma
[2]. Due to the lack of a precise definition of MAC, it is
difficult to interpret the data.
However, studies have shown that MAC is less likely to
respond to radiotherapy and conventional chemotherapy
[10, 11]. This may be due to the interference with im-
munologic recognition of tumor cells by masking anti-
genic epitopes and inhibiting lymphocytic infiltration [13].
LDM chemotherapy seems likely to work through com-
pletely different mechanisms than conventional chemo-
therapy. The mechanisms of LDM chemotherapy are
believed to be primarily related to inhibition of tumor
angiogenesis [14], which is also the target for vascular
endothelial growth factor inhibitors such as bevacizumab.
The anti-angiogenic effect of LDM chemotherapy is
believed to be due to either direct killing or inhibiting of
endothelial cells in the tumor vasculature, or killing of
bone-marrow-derived endothelial progenitor cells. Con-
tinuous administration of LDM chemotherapy prevents
endothelial cells from recovering, which leads to sustained
anti-angiogenic effect. In addition, studies have shown
that LDM chemotherapy stimulates the immune system
through inhibition of Treg cells, which leads to increased
activation of both tumor specific and tumor un-specific
effector cells. LDM also activates dendritic cells, thereby
further inducing the immune-stimulatory effect.
It has been shown that LDM chemotherapy, besides
directly affecting tumor cells, also enhances the effect of
targeting drugs. Most clinical trials have shown that
LDM chemotherapy is well tolerated; high grade toxicity
is rare or not found [14]. Many phase II studies have
shown the clinical benefit of LDM chemotherapy, in-
cluding promising tumor control rates and an excellent
safety profile [15].
The concept of LDM capecitabine has been success-
fully used predominately in breast cancer [16] but also
in metastatic CRC [17, 18]. Miger et al. [17] retrospect-
ively studied 35 patients with stage IV gastrointestinal
cancer that had been treated with LDM capecitabine.
Twenty-two of the patients had CRC. The treatment was
well-tolerated and 40 % of the patients with CRC had
stable disease after 2 months. Two of the patients with
CRC lived more than 24 months after initiating treat-
ment. These two patients both had MAC. Romiti et al.
[18] retrospectively studied 68 patients with recurrent
CRC that had been treated with LDM capecitabine. They
concluded that the treatment was well-tolerated and that
19 % of the patients were progression free for more than
6 months. The median overall survival was 23 months
for responders.
Fig. 3 Histologic hematoxylin and eosin stained paraffin section of
the patient’s tumor in the colon (a) and in the liver (b), respectively
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According to a recently published review, there have
been several studies analyzing the effect of the combin-
ation of LDM chemotherapy and bevacizumab in patients
with glioblastoma multiforme, metastatic ovarian cancer,
advanced breast cancer and non-small cell lung cancer
[19]. These studies have demonstrated clinical evidence of
anti-tumor efficacy, although interpretation of the studies
is generally limited by small sample sizes and lack of a
control arm. To our knowledge there is only one study
which has investigated the effect of LDM chemotherapy
and bevacizumab in patients with metastatic colorectal
cancer. This study, by Kelley et al., included 35 patients
that had received at least two previous lines of therapy,
before introducing the combination of cyclophosphamide
50 mg daily with imatinib 400 mg daily and bevacizumab
5 mg/kg every 2 weeks. The treatment was well tolerated
and led to prolonged (more than 6 months) stabilization
of the disease in 20 % of patients [20].
The current patient had a series of unfavorable prognos-
tic factors besides having a mucinous adenocarcinoma:
rapidly growing locally advanced tumor, thrombocytosis
[21] and KRAS mutation [22]. Conventional therapy
caused severe infections and a pulmonary embolism and
the dose was reduced (Fig. 3, Table 1). The result was
disappointing, since the tumor size was unaffected. Even
though the treatment was now focused on palliation, the
patient was young and highly motivated to receiving treat-
ment. The only thing deemed feasible was LDM capecita-
bine, which has been used in previous studies in our clinic
with promising results [17, 23]. The patient was followed
up frequently and when the treatment was well tolerated,
it was combined with bevacizumab. After 4 months, a re-
duction in tumor size was seen and the tumor center was
low attenuating according to the CT. Postoperatively the
center of the tumor was confirmed to be necrotic. Nine
months after surgery she was still recurrence free. To our
knowledge this is the only case where the cancer in a
patient with multifocal metastatic MAC with colorectal
origin has been successfully and completely eradicated.
Conclusion
LDM capecitabine in combination with bevacizumab
could be an attractive therapy option for treating patients
who are not eligible for more advanced treatment. As the
present case exemplifies, in addition to being feasible, it
could give a remarkable result. However, the described
case report highlights the need for future studies to evalu-
ate the outcome of this treatment.
Consent
Written informed consent has been obtained from the
patient for publication of this case report and accompany-
ing images. A copy of the written consent is available for
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